A new study published by the Journal Neurobiology of Disease has found that cannabidiol – a cannabinoid compound found in cannabis – can provide “long-lasting protection” against multiple sclerosis.
According to the study’s abstract, “Cannabidiol (CBD), a non-psychotropic cannabinoid constituent of Cannabis sativa, has potent anti-inflammatory and immunosuppressive properties”. Researchers state that; “Using this viral model of multiple sclerosis (MS), we demonstrate that CBD decreases the transmigration of blood leukocytes by downregulating the expression of vascular cell adhesion molecule-1 (VCAM-1), chemokines (CCL2 and CCL5) and the proinflammatory cytokine IL-1β, as well as by attenuating the activation of microglia”.
Researchers continue; “Moreover, CBD administration at the time of viral infection exerts long-lasting effects, ameliorating motor deficits in the chronic phase of the disease in conjunction with reduced microglial activation and pro-inflammatory cytokine production..
The study concludes; “Together, our findings highlight the anti-inflammatory effects of CBD in this viral model of MS and demonstrate the significant therapeutic potential of this compound for the treatment of pathologies with an inflammatory component.”
Researchers listed four primary highlights from the study:
CBD is a beneficial immune regulator in TMEV-IDD model, with long-term effects.
CBD treatment improves motor deficits in the chronic phase of TMEV-IDD.
CBD decreases VCAM-1, CCL2/CCL5 chemokines and TNFα/IL-1β.
Adenosine A2A receptors mediate some of the CBD effects both in vivo and in vitro.
The study was conducted by researchers at the Department of Functional and Systems Neurobiology at the Cajal Institute.